|
Re: Zometa in adjuvant for younger women
After reading the free paper, I don't get the sense the current research addresses ER-/Her2+. situation one way or the other. Keep in mind they are talking about benefits of Zometa beyond the usual bone issues it is typically prescribed for. If you have bone mets or osteoporosis, Zometa or Denosumab would seem a given. Whether you would benefit in terms of recurrence or slowing progression seems harder to decipher.
|